DocGo outlines $310M-$315M 2026 revenue outlook while targeting 75% mobile phlebotomy growth
DocGo (DCGO) presented its 2026 revenue guidance, projecting between $310 million and $315 million. The company aims for significant growth in its mobile phlebotomy services, targeting a 75% increase by 2026, alongside expanding its medical transportation segment. DocGo also anticipates profitability with an adjusted EBITDA of $40 million to $50 million by the same year.
How The DocGo (DCGO) Story Is Shifting As Transport Optimism Meets Lower Valuation Targets
DocGo's (DCGO) modeled fair value has been revised down from US$2.10 to US$1.87, reflecting a mixed outlook from analysts. While optimism surrounds its transport business, concerns about execution persist, leading to lower price targets like Stifel's US$2.50. The company recently updated its 2026 revenue guidance, repurchased shares, and is asking stockholders to vote on a potential reverse stock split and other proposals.
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
Analysts have updated their forecasts for DocGo Inc. (NASDAQ:DCGO) following its recent quarterly results. While revenue expectations for 2026 were slightly raised, loss per share predictions were also moderately increased, leading to an 11% reduction in the average price target to US$1.87. The company's revenue growth is expected to slow significantly compared to its historical performance and the wider industry.
DocGo (DCGO) price target decreased by 10.71% to 1.91
This article reports that the price target for DocGo (DCGO) has been decreased by 10.71%, bringing the new target to $1.91. No further details are provided regarding the reasons for this change or the entities that issued the revised target.
DocGo Inc. - Common Stock (NQ: DCGO
This article provides a list of recent press releases and news headlines concerning DocGo Inc. (DCGO), ranging from November 2023 back to April 2023. Key topics include several announcements of securities class action lawsuits against the company, quarterly earnings reports, certifications, new contracts, partnerships, and executive appointments. The stock price for DocGo Inc. is also displayed, showing a slight increase.
US$1.87: That's What Analysts Think DocGo Inc. (NASDAQ:DCGO) Is Worth After Its Latest Results
DocGo Inc. (NASDAQ:DCGO) shares fell after its latest quarterly results, leading analysts to update their forecasts. While revenue expectations for 2026 were slightly raised to US$306.3m, the projected loss per share widened to US$0.34. Consequently, the average price target for DocGo was cut by 11% to US$1.87, reflecting increased pessimism about the company's valuation.
DocGo (DCGO) CEO sees 15,644 RSU shares withheld for tax liability
DocGo Inc. CEO Lee Bienstock had 15,644 shares of common stock withheld at $0.59 per share on May 12, 2026, to cover tax liabilities from restricted stock units (RSUs). Following this transaction, Bienstock directly holds 2,801,826 shares. The RSUs were granted under the company's 2021 Stock Incentive Plan and are scheduled to vest in various installments through December 2028.
Strong demand for DocGo virtual care drives higher 2026 revenue target
DocGo Inc. (Nasdaq: DCGO) announced its first quarter 2026 financial results, revealing a revised and increased revenue outlook for the full year 2026 to $300-$315 million, up from previous guidance. This positive adjustment is attributed to strong demand and growth in its virtual care services, particularly through its subsidiary SteadyMD, and other core mobile health businesses. Despite a decline in overall Q1 revenue due to the winding down of migrant-related programs, revenue excluding these programs saw a significant increase, with the company focusing on achieving adjusted EBITDA profitability in the latter half of the year.
DocGo Inc. (DCGO) reports Q1 loss, beats revenue estimates
DocGo Inc. (DCGO) reported a Q1 loss but exceeded revenue estimates. This suggests the company is growing its top-line performance despite operating at a loss, which is common for companies in growth phases.
Needham Maintains DocGo(DCGO.US) With Buy Rating, Maintains Target Price $3
Needham has reiterated its Buy rating for DocGo (DCGO.US) and maintained its target price at $3. This indicates a continued positive outlook from the analyst firm regarding the company's stock performance.
DocGo Q1 Earnings Call Highlights
DocGo reported first-quarter revenue of $75.6 million and an adjusted EBITDA loss of $10.2 million. The company raised its 2026 revenue outlook due to strong performance in virtual care, medical transportation, and mobile health services, despite pressures from fuel costs and labor investments. CEO Lee Bienstock highlighted the growth of SteadyMD and new contracts, while CFO Norman Rosenberg addressed the impact of migrant-related project wind-downs on previous revenue figures.
DocGo Announces First Quarter 2026 Results
DocGo Inc. announced its financial results for the first quarter ended March 31, 2026, reporting total revenue of $75.6 million, a decrease from $96.0 million in Q1 2025 primarily due to the wind-down of migrant-related programs. Excluding these programs, revenue increased by 19.3%. The company also increased its full-year 2026 revenue guidance to $300-$315 million, driven by strong demand for virtual care services and growth in core business verticals.
DocGo (DCGO) Q1 2026 Earnings Transcript
DocGo (DCGO) reported Q1 2026 revenue of $75.6 million, with a decline attributed to the wind-down of migrant-related projects, though non-migrant revenues increased by 24% year over year. Virtual care offering SteadyMD and mobile phlebotomy are experiencing rapid growth, leading to an increased full-year revenue guidance to $300 million to $315 million. While the company faces temporary margin pressures from increased fuel costs and early operational expansion inefficiencies, management maintained its adjusted EBITDA loss guidance of $5 million to $10 million, anticipating improvements in profitability in the second half of 2026.
Earnings call transcript: DocGo’s Q1 2026 results show revenue beat but EPS miss
DocGo (DCGO) reported Q1 2026 revenue of $75.6 million, exceeding forecasts, but an EPS loss of $0.15 missed expectations. Despite the EPS miss and a decline in year-over-year revenue due to migrant-related project wind-downs, the stock rose 3.81% in after-hours trading, indicating positive investor sentiment regarding future growth. The company raised its 2026 revenue guidance to $300-$315 million and is focusing on expanding its SteadyMD platform and mobile health services, expecting profitability by Q3 2026.
DocGo (DCGO) Q1 2026 Earnings Transcript
DocGo (DCGO) reported Q1 2026 revenues of $75.6 million, exceeding expectations due to strong performance in its core Medical Transportation and Mobile Health segments, offsetting declines from discontinued migrant-related projects. The company raised its full-year revenue guidance to $300-$315 million but maintained its adjusted EBITDA loss guidance of $5-$10 million, citing temporary margin pressures from increased fuel costs and early-stage labor investments for rapid growth in SteadyMD. DocGo's strategic alternatives review is ongoing, with updates to be provided as available, while it focuses on expanding its virtual care, mobile phlebotomy, and "CareGap" services.
DocGo reports Q1 2026 revenue $75.6M, adjusted EBITDA ($10.2M) and raises 2026 revenue outlook
DocGo reported Q1 2026 revenue of $75.6 million and an adjusted EBITDA loss of $10.2 million, primarily due to the wind-down of migrant-related programs. Despite this, the company raised its full-year 2026 revenue guidance to $300–$315 million, driven by growth in its core mobile health services and medical transportation segments. Excluding migrant-related programs, revenue increased by 19.3%, with significant growth in Mobile Health Services and Medical Transportation Services.
DocGo (NASDAQ: DCGO) posts Q1 2026 loss but lifts full-year revenue outlook
DocGo (NASDAQ: DCGO) reported a Q1 2026 net loss of $16.7 million, up from an $11.1 million loss in the prior year, primarily due to higher operating and non-recurring costs. Despite a decrease in total revenue to $75.6 million from $96.0 million due to the wind-down of migrant-related programs, underlying revenue grew 19.3% when excluding those programs, driven by mobile health and virtual care services. The company raised its full-year 2026 revenue guidance to $300–$315 million but maintained its adjusted EBITDA outlook at negative $5–$10 million, citing increased hiring and fuel costs as pressures on profitability.
Number of shareholders of DocGo Inc. – BOATS:DCGO
This article focuses on the number of shareholders for DocGo Inc. (DCGO) as presented by BOATS (Blue Ocean Alternative Trade System) on TradingView. It provides market data and financial information related to the company, indicating that the market for DCGO was closed at the time of the article. The content appears to be a stub or a section of a larger financial data platform.
DocGo Inc expected to post a loss of 9 cents a share - Earnings Preview
DocGo Inc (DCGO) is anticipated to report a loss of 9 cents per share, according to an earnings preview. This forecast is based on information from Refinitiv.
DocGo (Nasdaq:DCGO) - Stock Analysis
DocGo (Nasdaq:DCGO) is a mobile healthcare services company operating in the US and UK, currently trading at US$0.57, which analysts believe is significantly undervalued. The company faces risks including volatile share price and declining earnings, but recently raised earnings guidance for FY2026 and announced an expansion of its clinical workforce for GLP-1 weight loss care. DocGo also received a Nasdaq minimum bid price non-compliance notice but is evaluating options to regain compliance.
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo (Nasdaq: DCGO) announced that CEO Lee Bienstock will present at the 21st Annual Needham Technology, Media, & Consumer Conference on May 14, 2026. He will deliver a company presentation and participate in one-on-one meetings, with a webcast available on DocGo's investor relations website. The company is a leading provider of technology-enabled medical transportation and mobile health services.
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo Inc. announced that CEO Lee Bienstock will deliver a presentation at the 21st Annual Needham Technology, Media, & Consumer Conference on Thursday, May 14, from 11:45 AM to 12:25 PM Eastern Time. A webcast of the presentation will be available on the investor relations section of DocGo’s website. DocGo is a leading provider of technology-enabled medical transportation and mobile health services, aiming to reshape traditional healthcare with proactive care delivery.
DocGo Announces Upcoming Participation at the 21st Annual Needham Technology, Media, & Consumer Conference
DocGo (Nasdaq: DCGO) announced that CEO Lee Bienstock will present at the 21st Annual Needham Technology, Media, & Consumer Conference on Thursday, May 14, at 11:45 AM ET. A webcast of the presentation will be available on the investor relations section of DocGo’s website. DocGo provides technology-enabled medical transportation and mobile health services, aiming to reshape healthcare delivery.
H+H taps DocGo subsidiary for up to $28M street medicine contract
NYC Health and Hospitals has awarded a contract worth up to $28 million to a DocGo subsidiary for street medicine services. The contract aims to provide mobile outreach for the homeless population in New York City. The article also mentions the date and time of publication.
DocGo Inc. (NASDAQ:DCGO) Sees Significant Increase in Short Interest
DocGo Inc. (NASDAQ:DCGO) experienced a significant 16.5% increase in short interest as of April 15th, totaling 6,400,268 shares, which represents about 6.7% of its outstanding shares. This rise in short interest, coupled with increased institutional investments from firms like Goldman Sachs and Millennium Management, indicates mixed investor sentiment. Analysts currently have a "Hold" consensus rating with an average target price of $2.38 for the stock.
DocGo Inc. (NASDAQ:DCGO) Given Average Recommendation of "Hold" by Brokerages
DocGo Inc. (NASDAQ:DCGO) has received an average "Hold" recommendation from seven brokerage firms, with an average 12-month price target of $2.375. Despite this, institutional investors have been increasing their stakes, notably AQR Capital Management LLC, which boosted its position by 219.1%. DocGo is a U.S.-based integrated healthcare company providing on-demand and mobile healthcare services, trading around $0.72 with a market capitalization of $71.01 million.
DocGo Ongoing Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against DocGo Inc. (NASDAQ: DCGO) and reminds investors of the December 26, 2023 lead plaintiff deadline in a federal securities class action. The lawsuit alleges that DocGo made false and misleading statements regarding executive hiring processes, the efficacy of its services, and the likelihood of reputational/regulatory scrutiny, leading to significant stock price drops following reports of issues with its New York City migrant relocation contract and the resignation of its CEO. Investors who suffered losses exceeding $100,000 are encouraged to contact the law firm.
DocGo stock surges on deal to acquire virtual care platform SteadyMD
DocGo (DG) stock surged after announcing its acquisition of virtual care platform SteadyMD. This strategic move aims to expand DocGo's telehealth capabilities and market presence, integrating SteadyMD's virtual primary care and specialty services into DocGo's existing mobile healthcare delivery model. The acquisition is expected to enhance DocGo's ability to provide comprehensive, on-demand healthcare solutions.
DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
DocGo Inc. (Nasdaq: DCGO) announced that it will release its financial results for the first quarter ended March 31, 2026, after market close on Monday, May 11, 2026. Management will host a conference call and webcast at 5:00 p.m. ET on the same day to discuss these results. The company, a leading provider of technology-enabled medical transportation and mobile health services, invites investors to access the webcast via its investor relations website.
DocGo to Announce First Quarter 2026 Results on Monday, May 11, 2026
DocGo Inc. announced it will release its financial results for the first quarter ended March 31, 2026, after the market closes on Monday, May 11, 2026. Management will host a conference call and webcast on the same day at 5:00 p.m. ET to discuss these results. The company, through its innovative care delivery platform, aims to reshape healthcare with mobile health services, remote patient monitoring, and ambulance services.
DCGO Price Today: DocGo Inc. Stock Price, Quote & Chart | MEXC
This article provides details on DocGo Inc. (DCGO) stock performance, trading information, and company overview. As of April 25, 2026, DCGO is trading at $0.72, showing a +3.90% increase from its previous close, although it has experienced a -68.04% decline over the last 12 months. The company operates in mobile health services and transportation, with a majority of its revenue from the Mobile Health Services segment.
DocGo (NASDAQ: DCGO) 2026 meeting to vote on reverse split, pay and charter changes
DocGo (NASDAQ: DCGO) has announced its 2026 annual meeting will include votes on a reverse stock split, executive compensation, and significant charter amendments. The company is seeking approval for a reverse stock split with a ratio between 1-for-5 and 1-for-10 to address Nasdaq's minimum bid price requirement and potentially boost investor interest. Stockholders will also vote on electing directors, approving an advisory resolution on executive pay, and charter changes related to corporate opportunities and officer liability exculpation, with full details provided in the definitive proxy statement.
DocGo Inc. 8-K SEC Filing Details for April 17, 2026 – Company Info, Address, Stock, and Compliance Status
DocGo Inc. has announced the resignation of Dr. Stephen K. Klasko from its Board of Directors, effective April 17, 2026. Following this, James Travers was appointed to the Audit & Compliance and Nominating and Corporate Governance Committees. The Board also formed a special committee, chaired by Michael Burdiek, to identify corporate efficiencies and cost reduction opportunities to accelerate profitability.
DocGo announces board changes and new special committee formation
DocGo (NASDAQ:DCGO) has announced changes to its board of directors and the formation of a new special committee. Dr. Stephen K. Klasko will step down from the board effective June 16, 2026, due to a new healthcare leadership role, and Michael Burdiek will become the new independent Chair of the Board. Additionally, a special committee has been formed to identify corporate efficiencies and cost reduction opportunities to accelerate profitability.
Stephen K. Klasko to Step Down from DocGo Board; Michael Burdiek Named Independent Chair
DocGo announced that Stephen K. Klasko will step down from its Board of Directors effective June 16, 2026, and Michael Burdiek will assume the role of independent Chair. Klasko is leaving to pursue a new significant healthcare leadership role. Additionally, Jim Travers and other board members have been appointed to various committees to fill vacancies and address efficiency efforts.
DocGo (NASDAQ: DCGO) shifts board leadership and adds profitability-focused committee
DocGo Inc. (NASDAQ: DCGO) announced significant changes to its board leadership, including Dr. Stephen K. Klasko's departure effective June 16, 2026, and the appointment of Michael Burdiek as independent Chair. The company also formed a new special committee, chaired by Burdiek, to identify corporate efficiencies and cost reduction opportunities to accelerate profitability. Jim Travers will assume Dr. Klasko's roles on the Audit and Compliance and Nominating and Corporate Governance Committees.
DCGO Should I Buy
DocGo Inc (DCGO) is not recommended as a good buy for beginner or long-term investors due to significant challenges in scaling its Mobile Health business and improving profitability. Analysts highlight mixed technical indicators, a sharp revenue decline in Q4 2025, and negative profitability. While some analysts maintain a "Buy" rating based on the transport segment's potential, the overall sentiment leans negative, suggesting a "Hold" stance.
Did DocGo Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Halper Sadeh LLP, an investor rights law firm, is investigating whether certain officers and directors of DocGo Inc. (NASDAQ: DCGO) breached their fiduciary duties to shareholders. The firm encourages long-term shareholders of DocGo to contact them to discuss potential legal rights and options, which could include corporate governance reforms, the return of funds to the company, or other relief. Shareholder involvement is emphasized as a way to improve company policies and enhance shareholder value.
DocGo (DCGO) price target decreased by 12.00% to 2.24
The article reports that DocGo's (DCGO) price target has been decreased by 12.00%, bringing it down to $2.24. No further details or analysis are provided in this brief update.
DocGo | PRE 14A: Preliminary proxy statements relating to merger or acquisition
This entry indicates that DocGo has filed a PRE 14A document with the SEC. A PRE 14A filing typically relates to preliminary proxy statements concerning a merger or acquisition, signaling that the company is involved in discussions or plans for such a corporate action.
DocGo Inc. (DCGO) Stock Price, News, Quote & History
DocGo Inc. (DCGO) stock is currently trading at $0.5768, showing a 4.91% increase. The company operates in mobile healthcare services, providing both mobile health and transportation services in the US and UK. Despite a positive daily performance, the stock has seen significant declines over longer periods and analysts have an average target price of $2.10, with the latest rating being a "Hold."
DocGo Inc. (NASDAQ:DCGO) Given Average Rating of "Hold" by Brokerages
DocGo Inc. (NASDAQ:DCGO) has received an average "Hold" rating from seven brokerage firms, with an average 12-month price target of $2.375. The company's shares are currently trading around $0.57, below its 50-day and 200-day moving averages. Institutional investors and hedge funds own approximately 56.44% of the company, with several firms recently initiating or increasing their positions.
DocGo Inc. (DCGO) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for DocGo Inc. (DCGO) stock, showing its current price as $0.5752 with a 0.91% increase. It includes information on analyst ratings (currently none available) and advises that earnings information is not yet provided. The page also features promotional content for trading conferences and platforms.
DocGo (DCGO) CEO Bienstock has 18,811 shares withheld to cover RSU taxes
DocGo Inc.'s CEO, Lee Bienstock, had 18,811 shares of common stock withheld to cover tax liabilities associated with previously granted restricted stock units (RSUs). These shares were valued at $0.57 each and were withheld rather than sold on the open market. Following this transaction, Bienstock directly holds 2,817,470 shares of DocGo Common Stock.
DocGo (DCGO) price target decreased by 12.00% to 2.24
This article reports that the price target for DocGo (DCGO) has been decreased by 12.00%, bringing it down to $2.24. No further details regarding the reasons for this change or the issuing analyst are provided.
[SCHEDULE 13G/A] DocGo Inc. Amended Passive Investment Disclosure
The Vanguard Group filed an amended Schedule 13G/A for DocGo Inc., reporting 0% beneficial ownership due to an internal realignment effective January 12, 2026. This administrative filing clarifies reporting responsibilities among Vanguard entities, indicating that what appears to be a disposition is actually a disaggregation of reporting, and affirms no single outside holder owns more than 5%. Subsequent filings from Vanguard's separate entities may show where these holdings are now reported.
DocGo (NASDAQ:DCGO) Given New $1.00 Price Target at Canaccord Genuity Group
Canaccord Genuity Group has lowered its price target for DocGo (NASDAQ:DCGO) from $1.50 to $1.00, maintaining a "hold" rating, despite other firms holding higher targets. DocGo's stock is currently trading around $0.63 with a market capitalization of $62.21 million, and institutional investors own a significant portion of the company. The company, an integrated healthcare provider offering on-demand mobile services, has seen mixed analyst ratings with an average price target of $2.38.
Canaccord cuts DocGo stock price target on profitability concerns
Canaccord has lowered its price target for DocGo (NASDAQ:DCGO) to $1.00 from $1.50, citing concerns over profitability despite exceeding revenue estimates in Q4 2025. The company's adjusted EBITDA came in below estimates, though core transportation and mobile health volumes were strong, prompting raised 2026 guidance. DocGo aims for adjusted EBITDA profitability in the second half of 2026, and analysts suggest the stock may be undervalued with recovery potential.
Ethisphere Names DocGo as One of the 2026 World's Most Ethical Companies®
DocGo Inc. has been recognized by Ethisphere as one of the 2026 World's Most Ethical Companies®, marking its first time receiving this honor. The company is one of only four healthcare providers and services companies to be recognized, highlighting its commitment to ethical business practices and strong governance. DocGo's CEO, Lee Bienstock, emphasized that trust is at the core of their operations, influencing everything from patient care to data security.
Healthcare provider DocGo joins 2026 World's Most Ethical Companies list
DocGo (Nasdaq: DCGO), a provider of medical transportation and mobile health services, has been named one of the 2026 World's Most Ethical Companies by Ethisphere. This marks DocGo's first time receiving this honor, recognizing its commitment to business integrity through robust ethics, compliance, and governance programs. DocGo is one of only four honorees in the healthcare providers and services category, which CEO Lee Bienstock attributes to prioritizing trust, strong governance, accountability, and a culture of integrity.
